BioScreening - organic compounds for screening

08.06.2005 Research and Markets: The Development of Specific Model Systems Suited for Specific Disease Areas (Such as Oncology) is an Unmet Need
DUBLIN, Ireland, June 8 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/reports/c18782 ) has announced the addition of Model Organisms in Drug Discovery and Development: An Industry Analysis to their offering. (Logo: http://www.newscom.com/cgi-bin/prnh/20040820/RESEARCH ) 'Model Organisms in Drug Discovery and Development: An Industry Analysis' maps the market opportunity and trends apparent in the model organisms' space as they relate [...]
More bioscreening news...

07.06.2005 Euroscreen Receives Key US Patent Covering Screening Methods Using CCR5 Chemokine Receptor
Chemokine Receptor is a Crucial Target for a Novel AIDS Therapy. Euroscreen s.a., a world leader in G-protein-coupled receptors (GPCRs), today announced the issue of a key US patent in the area of HIV infection. The patent claims screening methods using the human CCR5 receptor. Euroscreen s.a., a world leader in G-protein-coupled receptors (GPCRs), today [...]
More bioscreening news...

07.06.2005 Plexxikon Signs Broad Kinase Screening Collaboration With Invitrogen
Plexxikon Inc. today announced an agreement under which Invitrogen Corporation will profile Plexxikon's proprietary kinase inhibitor libraries. These libraries represent high-value drug discovery assets based on eight different scaffolds, or chemotypes, with co-crystal structural information available and pharmaceutical properties profiled for many compounds. Under the agreement, Plexxikon's libraries will be screened in parallel against the [...]
More bioscreening news...

07.06.2005 Arena Pharmaceuticals Issued Patent for Drug Screening Methods for Treatment of Metabolic-Related Disorders
Patent is Part of Collaboration with Merck & Co., Inc. to Discover and Develop Potential Therapies for Cardiovascular Disease SAN DIEGO, June 7 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA - News) announced today that it was issued U.S. patent number 6,902,902, entitled "Human G Protein-Coupled Receptors and Modulators Thereof for the Treatment of Metabolic-Related Disorders," [...]
More bioscreening news...

07.06.2005 Maxim Pharmaceuticals Announces Publication on the Identification of TIP47, A Novel Pathway and Molecular Target in Apoptosis
SAN DIEGO--(BUSINESS WIRE)--June 7, 2005--Maxim Pharmaceuticals, Inc. (NASDAQ:MAXM)(SSE:MAXM) today announced the publication of an article in the Journal of Molecular Cancer Therapeutics (4:761-771, 2005), which describes the discovery of a class of apoptosis-inducing 3,5-diaryl-1,2,4-oxadiazoles and their molecular target, TIP47, an IGF-II receptor binding protein, as a novel pathway for activation of apoptosis. This publication also [...]
More bioscreening news...

09.06.2005 Effective cancer treatments follow the clock
Oncologists have long thought that cancer treatments tend to be more effective at certain times of day. But they have been unable to turn this knowledge into practice, because they did not understand the phenomenon well enough. Now, researchers have discovered a molecular mechanism that explains why sensitivity to anti-cancer drugs changes with the clock. [...]
More bioscreening news...

09.06.2005 Researchers identify drug as therapeutic candidate for spinal muscular atrophy
Scientists develop data analysis tool, screen more than 47,000 compounds - Using a newly developed technology, a team of Columbia University researchers has uncovered that indoprofen, a nonsteroidal anti-inflammatory drug, may increase the production of a protein lacking in patients with spinal muscular atrophy (SMA), a fatal pediatric genetic disease. It is the scientists' hope that the [...]
More bioscreening news...

13.06.2005 Thermo Electron Corp.
Patricia Henson, Raman Product Manager In order to better understand solid state compounds that are candidates for new drugs, pharmaceutical companies are employing new technologies in the screening of hundreds of compounds on a daily basis. An important factor in solid state drug forms is polymorphism—a solid-state phenomenon whereby an element or compound can exist in [...]
More bioscreening news...

13.06.2005 Leerink Swann & Company Initiates Coverage of Illumina, Inc. (NASDAQ: ILMN)
BOSTON, MA -- (MARKET WIRE) -- 06/10/2005 -- This morning, Senior Biotechnology and Life Sciences Analyst John L. Sullivan initiated coverage of Illumina, Inc. with an Outperform rating. Mr. Sullivan bases his investment thesis on his belief that the competitive landscape in the genotyping products market has yet to be set, and market share is [...]
More bioscreening news...

13.06.2005 KineMed, Inc. Announces Presentations at The American Diabetes Association’s Annual Scientific Conference in San Diego, California
EMERYVILLE, Calif., June 9 /PRNewswire/ -- KineMed, Inc., a platform-based drug development and advanced medical diagnostics company, announced today that it will make presentations related to two new product programs at the American Diabetes Association's 65th Annual Scientific Sessions to be held in San Diego on June 10-14. KineMed will present its KineMarker(TM) assays for [...]
More bioscreening news...

14.06.2005 Ion Channel Targets Agenda Complete
Select Conferences are pleased to announce their first conference on the fast developing area of ion channel drug targets to be held 20-21 Sept 2005 in Waltham, near Boston, MA. This will provide a major forum to present cutting edge work within this dynamic field and an un-missable event for those wishing to keep [...]
More bioscreening news...

15.06.2005 Diversity Orientated Synthesis (DOS) Agenda Complete
- Combinatorial chemistry has evolved from the concept of producing massive numbers of compounds to smaller, more focused libraries. Now is a good time to review the current thinking and state-of-the art in Diversity Oriented Synthesis so, Select Conferences are pleased to announce their first conference focused in this area. To be held 22-23 [...]
More bioscreening news...

21.06.2005 KU Researchers Win $8M NIH Contract to Find Compounds for Male Contraception
Researchers at the University of Kansas and the University of Kansas Medical Center have won an almost $8 million National Institutes of Health contract to find chemical compounds to develop into reversible male contraceptives that do not rely on steroids or affect bodily hormones. Science & TechnologyLawrence, Kan. - infoZine - The five-year contract will allow [...]
More bioscreening news...

23.06.2005 ChemDiv and AdipoGenix Extend Discovery and Medicinal Chemistry Collaboration
ChemDiv and AdipoGenix Extend Discovery and Medicinal Chemistry Collaboration SAN DIEGO, and BOSTON, June 23 /PRNewswire/ -- ChemDiv, Inc. and AdipoGenix, Inc. have announced that AdipoGenix has been awarded a SBIR grant from NIDDK for a collaboration with ChemDiv to further progress small molecules that target human fat tissue as therapy for obesity and type 2 [...]
More bioscreening news...

new | june 2010 | october 2009 | may 2009 | january 2009 | october 2008 | april 2008 | january 2008 | october 2007 | september 2007 | august 2007 | march 2007 | february 2007 | january 2007 | december 2007 | september 2006 | august 2006 | july 2006 | june 2006 | may 2006 | april 2006 | march 2006 | january 2006 | november 2005 | august 2005 | july 2005 | june 2005 | may 2005 | april 2005 | march 2005 | december 2005 | november 2004 | october 2004 | september 2004 | august 2004 | july 2004 | june 2004 | may 2004 | april 2004 | march 2004 | february 2004 | january 2004 | december 2004 | november 2003 | october 2003 | september 2003 | august 2003 | july 2003 | june 2003 | may 2003